Methodological innovations and stakeholder involvement in core outcome sets for skin diseases: a survey of the C3 working groups

Funding

Dr. Garg is an advisor for AbbVie, Aclaris Therapeutics, Anaptys Bio, Aristea Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Cosmo Pharma, Incyte, Insmed, Janssen, Novartis, Pfizer, Sonoma Biotherapeutics, UCB, Union Therapeutics, Ventyx Biosciences, and Viela Biosciences, and receives honoraria. Dr. Garg receives research grants from AbbVie, UCB, National Psoriasis Foundation, and CHORD COUSIN Collaboration (C3). He is the co-copyright holder of the HS-IGA and HiSQOL instruments. Dr Ingram receives a stipend as Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate. He is a consultant for Abbvie, Boehringer Ingelheim, ChemoCentryx, Citryll, Novartis, UCB Pharma, and UNION Therapeutics and has served on advisory boards for Insmed, Kymera Therapeutics, and Viela Bio. He is the co-copyright holder of HiSQOL and Investigator Global Assessment instruments for HS. His department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. He is the Treasurer of the CHORD-COUSIN Collaboration (C3).